Stock Analysis, Dividends, Split History
RTTR / Ritter Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||12.90|
|Enterprise Value ($M)||-5.35|
|Book Value ($M)||14.92|
|Book Value / Share||2.70|
|Price / Book||0.73|
|NCAV / Share||n/a|
|Price / NCAV||n/a|
|Preferred Stock Shares Outstanding||9,140|
|Common Stock Shares Outstanding||49,406,521|
|Common Shares Outstanding||49,406,521|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||-0.39|
|Return on Assets (ROA)||-1.09|
|Return on Equity (ROE)||-1.92|
|Income Statement (mra) ($M)|
|Earnings Per Share Basic And Diluted||-0.50|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||-7.40|
|Cash from Investing||-0.01|
|Cash from Financing||-0.01|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1460702|
|SIC 2834 - Pharmaceutical Preparations|
Stock splits are used by Ritter Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2017-11-11 - Asif
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Ritter Pharmaceuticals is advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient’s health. The company completed a Phase 2a clinical trial of its leading product candidate, RP-G28, an orally administered, high purity oligosaccharide in November 2011. The company completed a Phase 2b/3 multi-center, randomized, double-blind, placebo-controlled, parallel group trial of RP-G28 in October 2016. The purpose of the trial was to evaluate the safety, efficacy and tolerability of two dosing regimens of RP-G28 in patients with moderate to severe lactose intolerance symptoms. Enrollment was initiated in March 2016 and completed in August 2016, achieving its projected enrollment time pe...
10h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
11h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
11h - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
Related News Stories
Discussion: Array Biopharma’s (ARRY) combo treatment of encorafenib and binimetinib for patients with advanced melanoma associated with a BRAF mutation receives FDA approval. However, stocks are marginally down by -3.97% at yesterday’s closing of market. However, over the last 52-wk the stock price has risen almost at a steady rate from its 52-wk low of $7.15 to almost treble to June 20 peak of $20. (485-3)
A cyclical bottom (maybe?), a special situation, and a consolidating industry leader mark the long side. (53-0)
With just $7.8M market capitalization and 13 full-time employees, Endra Life Sciences (NASDAQ:NDRA) was part of all financial news sources yesterday when its stock prices jumped +58.1%. The company was incorporated in 2007 and offered its IPO in May 2017. The IPO was priced at $5 and is still close to the all-time high the stock price ever reached. At 3.50 pm June 4 the stock reached its recent nadir at $1. (572-1)
There are a number of red flags that suggest this asset is worthless, and the chances of it ever making it to the market are slim to none. (15-3)
Alnylam (NASDAQ:ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue, despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs elsewhere to have been able to do better on the EPS front. The stock showed slightly positive improvement on the news. However, there are a number of upcoming catalysts that will probably help the stock even further. (49-1)
Silicon Investor Message Boards
This table lists all message boards related to RTTR / Ritter Pharmaceuticals, Inc. on message board site Silicon Investor.
|Rttrader.com and or InvestIn.com||Rttrader.com and or InvestIn.com||Rttrader.com and or InvestIn.com|
as of ET